Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436986 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL389351 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL29436985 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL489493 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL389352 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL7431612 | 0.93 | CYP3A4 (0.48) | MMEANPEPCYP3A4CYP2C19GAA | |
| SCHEMBL7431614 | 0.93 | CYP3A4 (0.48) | MMEANPEPCYP3A4CYP2C19GAA | |
| SCHEMBL28000637 | 0.90 | MME (0.47) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL21239953 | 0.89 | LTA4H (0.53) | MMEANPEPLTA4H | |
| SCHEMBL21239952 | 0.89 | LTA4H (0.53) | MMEANPEPLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230330028-A1 | PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS | EB IP HYBRITABS B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-20230113114-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | Accencio LLC | 2023-04-13 | — | — | US | disclosed |
| CN-109414402-B | Method for preparing a drug delivery system with a testosterone compound present externally or topically and such a drug delivery system | EB IP希博里塔布斯有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | MME, CTSC, REN | MME 1/4885ANPEP 13/4885PPID 2569/4885 |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | MME 1/4885ANPEP 13/4885PPID 2569/4885 |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | MME 4/4885ANPEP 12/4885PPID 2019/4885 |
| US-20230113114-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | ACE, ACE2, TMPRSS2 | MME 4/4885ANPEP 12/4885PPID 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.